| Ident. | Authors (with country if any) | Title |
|---|
| 002833 (2013) |
Kristian Thorlund [Canada] ; Eric Druyts [Canada] ; J Antonio Avi A-Zubieta [Canada] ; Ping Wu [Canada] ; Edward J. Mills [Canada] | Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings |
| 002834 (2013) |
Daniel E. Furst [États-Unis] ; Edward Clark Keystone [Canada] ; Alexander K. So [États-Unis, Canada, Allemagne, Pays-Bas, Italie, Royaume-Uni, Autriche] ; Jürgen Braun [Allemagne] ; Ferry C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Italie] ; Fabrizio De Benedetti [Allemagne] ; Thomas Dörner [Allemagne] ; Paul Emery [Royaume-Uni] ; Roy Fleischmann [États-Unis] ; Allan Gibofsky [États-Unis] ; J R Kalden [Allemagne] ; Arthur Kavanaugh [États-Unis] ; Bruce Kirkham [Royaume-Uni] ; Philip Mease [États-Unis] ; A. Rubbert-Roth [Allemagne] ; Joachim Sieper [Allemagne] ; Nora G. Singer [États-Unis] ; Josef S. Smolen [Autriche] ; Piet L C M. Van Riel [Pays-Bas] ; Michael H. Weisman [États-Unis] ; Kevin L. Winthrop [États-Unis] | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 |
| 002861 (2013) |
Yvonne C. Lee [États-Unis] ; Bing Lu [États-Unis] ; Gilles Boire [Canada] ; Boulos Paul Haraoui [Canada] ; Carol A. Hitchon [Canada] ; Janet E. Pope [Canada] ; J Carter Thorne [Canada] ; Edward Clark Keystone [Canada] ; Daniel H. Solomon [États-Unis] ; Vivian P. Bykerk [États-Unis, Canada] | Incidence and predictors of secondary fibromyalgia in an early arthritis cohort |
| 002866 (2013) |
Markku Hakala [Finlande] ; Kai Immonen [Finlande] ; Markku Korpela [Finlande] ; Mikko Vasala [Finlande] ; Markku J. Kauppi [Finlande] | Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis |
| 002878 (2013) |
Monika M. Schoels [Autriche] ; Désirée Van Der Heijde [Pays-Bas] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho M. Murikama [Japon] ; Norihiro Nishimoto [Japon] ; Josef S. Smolen [Autriche] | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement |
| 002879 (2013) |
Paul Emery [Royaume-Uni] ; Anthony Sebba [États-Unis] ; Tom W J. Huizinga [Pays-Bas] | Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis |
| 002B59 (2013) |
R. F. Van Vollenhoven [Suède] ; P. Emery [Royaume-Uni] ; C. O. Bingham [États-Unis] ; E. Keystone [Canada] ; R. M. Fleischmann [États-Unis] ; D. Furst [États-Unis] ; E. W. Hessey [Royaume-Uni] ; A. Vashishtha [États-Unis] ; A. Mehbob [Royaume-Uni] ; P. B. Lehane [Royaume-Uni] | SAT0131 Long-Term Safety of Rituximab: Pooled Analysis of the Rheumatoid Arthritis Global Clinical Trial Programme Over 11 Years |
| 002B60 (2013) |
R. Christensen [Danemark] ; S. Tarp [Danemark] ; D. E. Furst [États-Unis] ; M. Stergaard ; T. Lorenzen ; M. S. Hansen [Danemark] ; J. A. Singh [États-Unis] ; E. H. Choy [Royaume-Uni] ; M. Boers [Pays-Bas] ; M. E. Suarez-Almazor [États-Unis] ; B. Ejbjerg [Danemark] ; L. E. Kristensen [Suède] ; H. Bliddal [Danemark] | SAT0130 Defining the Optimal Biological Monotherapy in Rheumatoid Arthritis (RA): Network Meta-Analysis of Randomized Trials |
| 002B61 (2013) |
R. Fleischmann [États-Unis] ; M. Weinblatt [États-Unis] ; M. Schiff ; D. Khanna ; L. Rosenblatt ; M. Maldonado ; D. Furst [États-Unis] | SAT0129 Improved Quality of Life, Work Productivity, General Activity and Independence in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results from the Ample Trial |
| 002C00 (2013) |
S. F. Ling ; S. Chitale [Royaume-Uni] ; C. Estrach ; R. J. Moots ; N. Goodson | SAT0049 Obesity is Associated with Reduced Improvement in Functional Disability After 1 Year of Treatment: Results from an Inception Early Rheumatoid Arthritis Cohort |
| 002C01 (2013) |
S. Mansouri ; F. E. Abourazzak ; A. Najdi [Maroc] ; L. Tahiri ; C. Nejjari [Maroc] ; T. Harzy | SAT0048 Prevalence of Metabolic Syndrome in Patients with Rheumatoid Arthritis in Morocco: A Cross-Sectional Study of 179 Cases. |
| 002E66 (2013) |
T. Huynh [Danemark] ; A. Stergaard [Danemark] ; C. Egsmose [Danemark] ; O. Rintek Madsen [Danemark] | FRI0177 Patient and health professional preferences to route of administration of biologic agents for ra treatment |
| 002F62 (2013) |
| Abstract |
| 002F65 (2013) |
| ARA Scientific Posters |
| 003202 (2013) |
K. Ayabe ; K. Takeuchi ; M. Matsushita ; Y. Tamura [Japon] ; T. Sakurai [Japon] ; H. Inoue [Japon] | AB0318 Abatacept (abt) equivalent to anti-tumor necrosis factor a (tnfa) in terms of joint destruction inhibition: multicenter study of 107 patients treated for 52 weeks |
| 003203 (2013) |
K. Pavelka [République tchèque] ; K. Hejduk [République tchèque] ; H. Mann [République tchèque] ; E. Dokoupilova ; D. Suchy [République tchèque] | AB0317 Swollen joints- the only predictor of achieving low disease activity in ra with tocilizumab therapy in czech national registry attra |
| 003206 (2013) |
K. Fragiadaki [Grèce] ; K. Makrilakis [Grèce] ; J. Smith [Royaume-Uni] ; P. P. Sfikakis [Grèce] ; G. D. Kitas [Royaume-Uni] | AB0316 Changes of adipokine serum levels after il-6 receptor blockade with tocilizumab in patients with rheumatoid arthritis |
| 003270 (2013) |
S. Mizuki [Japon] ; T. Murakami [Japon] ; K. Oryoji [Japon] ; K. Kamada [Japon] ; E. Yokota [Japon] | AB0256 Risk factors associated with generalized bone loss in patients with rheumatoid arthritis: retrospective longitudinal study. |
| 003550 (2012) |
D E Furst [États-Unis] ; E C Keystone [Canada] ; J. Braun [Allemagne] ; F C Breedveld [Pays-Bas] ; G R Burmester [Allemagne] ; F. De Benedetti [Italie] ; T. Dörner [Allemagne] ; P. Emery [Royaume-Uni] ; R. Fleischmann [États-Unis] ; A. Gibofsky [États-Unis] ; J R Kalden [Allemagne] ; A. Kavanaugh [États-Unis] ; B. Kirkham [Royaume-Uni] ; P. Mease [États-Unis] ; J. Sieper [Allemagne] ; N G Singer [États-Unis] ; J S Smolen [Autriche] ; P L C M. Van Riel [Pays-Bas] ; M H Weisman [États-Unis] ; K. Winthrop [États-Unis] | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 |
| 003551 (2012) |
Yukitomo Urata [Japon] ; Ryoko Uesato [Japon] ; Dai Tanaka [Japon] ; Yoshihide Nakamura [Japon] ; Shigeru Motomura [Japon] | Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study |
| 003560 (2012) |
J E Gottenberg [France] ; P. Ravaud [France] ; A. Cantagrel [France] ; B. Combe [France] ; R M Flipo [France] ; T. Schaeverbeke [France] ; E. Houvenagel [France] ; P. Gaudin [France] ; D. Loeuille [France] ; S. Rist [France] ; M. Dougados [France] ; J. Sibilia [France] ; X. Le Loët [France] ; C. Marcelli [France] ; T. Bardin [France] ; I. Pane [France] ; G. Baron [France] ; X. Mariette [France] | Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry |
